00:57 , Sep 15, 2015 |  BC Extra  |  Financial News

Acacia plans L150M IPO

Acacia Pharma Ltd. (Cambridge, U.K.) plans to raise L150 million ($232 million) in an IPO on the London Stock Exchange in October, according to a person familiar with the company. JPMorgan Cazenove and Canaccord are...
01:42 , Oct 8, 2014 |  BC Extra  |  Clinical News

Acacia seeks options after hitting in PONV Phase III

Acacia Pharma Ltd. (Cambridge, U.K.) said its lead product APD421 reduced the incidence of post-operative nausea and vomiting in two Phase III trials of adult surgical patients at moderate to high risk for PONV. Acacia,...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

APD515: Phase II data

A double-blind, crossover, U.K. and Danish Phase II trial in 32 advanced cancer patients with persistent dry mouth showed that 20 mg APD515 given 4 times daily met the primary endpoint of reducing symptoms of...
23:15 , Oct 15, 2013 |  BC Extra  |  Clinical News

Acacia reports Phase II dry mouth data

Acacia Pharma Ltd. (Cambridge, U.K.) said APD515 given four times daily met the primary endpoint of reducing dry mouth symptoms at day seven vs. placebo in a 32-patient Phase II trial in advanced cancer patients...
07:00 , Aug 1, 2011 |  BC Week In Review  |  Clinical News

APD515: Phase II started

Acacia began a double-blind, placebo-controlled, crossover, U.K. and Danish Phase II trial to evaluate 20 mg APD515 given 4 times daily for 7 days in about 30 patients. Acacia Pharma Ltd. , Cambridge, U.K.  ...
00:10 , Apr 1, 2011 |  BC Extra  |  Financial News

Acacia raises $10 million

Acacia Pharma Ltd. (Cambridge, U.K.) raised $10 million in a series A round. New investor Lundbeckfond Ventures joined existing investor Gilde Healthcare. Lundbeckfond's Johan Kordel will join Acacia's board. Acacia's APD421 is in Phase IIa...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Clinical News

APD515: Phase I data

A Phase I trial in healthy volunteers showed that oral and topical APD515 were well tolerated with no serious adverse events or significant changes in blood chemistry reported. Acacia Pharma Ltd. , Cambridge, U.K.  ...
08:00 , Jan 10, 2011 |  BC Week In Review  |  Clinical News

APD515: Phase I started

Acacia began a Phase I trial to evaluate ascending doses of topical and oral APD515 in healthy volunteers. Acacia Pharma Ltd. , Cambridge, U.K.   Product: APD515   Business: Other   Molecular target: NA  ...